Education
About Us
Working with TipRanks
Follow Us
Exagen Inc (XGN)
NASDAQ:XGN
XGN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.30 - $6.22
Previous CloseN/A
Volume15.94K
Average Volume (3M)157.93K
Market Cap
$61.02M
Enterprise Value$57.93M
Total Cash (Recent Filing)$13.16M
Total Debt (Recent Filing)$24.70M
Price to Earnings (P/E)―
Beta0.93
Next Earnings
Mar 11, 2025EPS Estimate
-0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.94
Shares Outstanding17,637,278
10 Day Avg. Volume72,641
30 Day Avg. Volume157,925
Standard Deviation0.20
R-Squared0.14
Alpha-0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.09
Price to Cash Flow (P/CF)-7.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.95
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit1.97
Enterprise Value/Ebitda-4.50
Forecast
1Y Price Target
$7.00Price Target Upside102.31% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Exagen News
PremiumCompany Announcements
Exagen Inc. Reports Q3 2024 Financial Results
PremiumPre-Earnings
Is XGN a Buy, Before Earnings?
PremiumPre-Earnings
Is XGN a Buy, Before Earnings?---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceEfforts to increase average selling price (ASP) and reduce cash burn are yielding positive results for Exagen.
Product LaunchXGN is expected to launch an enhanced version of its ADVISE test with 5 new markers intended to drive better Dx rates and expand the TAM.
Bears Say
Revenue ExpectationsExagen's 3Q24 results were below estimates due to one-time adjustments, leading to a decrease in revenue guidance for 2024.
---
Ownership Overview
36.31% Insiders
5.93% Mutual Funds
20.83% Other Institutional Investors
34.22% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
XGN FAQ
What was Exagen Inc’s price range in the past 12 months?
Exagen Inc lowest stock price was $1.30 and its highest was $6.22 in the past 12 months.
What is Exagen Inc’s market cap?
Exagen Inc’s market cap is $61.02M.
When is Exagen Inc’s upcoming earnings report date?
Exagen Inc’s upcoming earnings report date is Mar 11, 2025 which is in 7 days.
How were Exagen Inc’s earnings last quarter?
Exagen Inc released its earnings results on Nov 12, 2024. The company reported -$0.28 earnings per share for the quarter, beating the consensus estimate of -$0.29 by $0.01.
Is Exagen Inc overvalued?
According to Wall Street analysts Exagen Inc’s price is currently Undervalued.
Does Exagen Inc pay dividends?
Exagen Inc does not currently pay dividends.
What is Exagen Inc’s EPS estimate?
Exagen Inc’s EPS estimate is -0.26.
How many shares outstanding does Exagen Inc have?
Exagen Inc has 17,637,278 shares outstanding.
What happened to Exagen Inc’s price movement after its last earnings report?
Exagen Inc reported an EPS of -$0.28 in its last earnings report, beating expectations of -$0.29. Following the earnings report the stock price went down -6.061%.
Which hedge fund is a major shareholder of Exagen Inc?
Currently, no hedge funds are holding shares in XGN
---
Exagen Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.00 (102.31% Upside)
$7.00 (102.31% Upside)
Hedge Fund Trend
Increased
By 418.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $660.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 6.0%
Last 30 Days ▼ 6.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
84.04%
12-Months-Change
Fundamentals
Return on Equity
-83.86%
Trailing 12-Months
Asset Growth
-28.43%
Trailing 12-Months
Company Description
Exagen Inc
Exagen Diagnostics Inc was incorporated under the laws of the state of New Mexico in 2002. The Company is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets four products under its Avise brand to provide an accurate, timely and differential diagnosis and to optimize the treatment of ARDs. It processed approximately 9,300 patient specimens for its diagnostic product line, Avise SLE. It markets and sells solutions to community rheumatologists.
---
XGN Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in expanding ASP and managing costs effectively, setting the stage for future growth with the launch of new biomarkers. However, it also pointed to onetime adjustments affecting revenue and margin, alongside challenges from external factors like weather disruptions. The sentiment is cautiously optimistic, with a focus on long-term growth and profitability.Read More>---
XGN Stock 12 Month Forecast
Average Price Target
$7.00
▲(102.31% Upside)
Technical Analysis
Best Analysts Covering XGN
1 Year
1 Year Success Rate
6/13 ratings generated profit
1 Year Average Return
+12.65%
reiterated a buy rating 2 months ago
Copying Kyle Mikson CFA's trades and holding each position for 1 Year would result in 46.15% of your transactions generating a profit, with an average return of +12.65% per trade.
---